BCR and B-cell chronic lymphocytic leukemia: The late, indirect effect was a major contribution toward a paradigm change in CLL treatment brought about by the advent of BcR signaling inhibitors (BCRi) i.e., ibrutinib, a BTK inhibitor, and idelalisib, a PI3Kδ inhibitor (133, 134).